# Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

> **NCT02477969** · PHASE3 · UNKNOWN · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 587 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** PEX168(100µg)
- **DRUG:** PEX168(200µg)
- **DRUG:** Placebo
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT02477969
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-02-27
- **Primary completion:** 2016-06-22
- **Final completion:** 2017-06
- **Target enrollment:** 587 (ACTUAL)
- **Last updated:** 2017-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02477969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02477969, "Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT02477969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*